File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Low-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients

TitleLow-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients
Authors
Issue Date2005
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH
Citation
Journal Of Gastroenterology And Hepatology, 2005, v. 20 n. 6, p. 935-940 How to Cite?
AbstractBackground: Rabeprazole in combination with amoxicillin and metronidazole (RAM) has been shown to be an effective second-line treatment of Helicobacter pylori infection. The effects were compared of 7-day low-dose and high dose rabeprazole in RAM for the primary treatment of H. pylori infection in Chinese patients. Methods: Helicobacter pylori-positive dyspeptic patients were randomized to receive either (i) rabeprazole 10 mg, amoxicillin 1000 mg and metronidazole 400 mg (RAM-10) or (ii) high-dose rabeprazole 20 mg, amoxicillin 1000 mg and metronidazole 400 mg (RAM-20), each given twice daily for 7 days. Helicobacter pylori eradication was confirmed by 13C-urea breath test 5 weeks after stopping medications. Side-effects of treatments were documented. Results: A total of 120 patients were eligible for analysis. By intention-to-treat and per-protocol analysis, the eradication rates were 83% and 86% in the RAM-10 group and 75% and 76% in the RAM-20 group, respectively (P = 0.26 and P = 0.17). Both regimens were well-tolerated and compliance was >98% in both groups. Conclusions: Low-dose rabeprazole in combination with amoxicillin and metronidazole is an effective, economical and well-tolerated therapy for the treatment of H. pylori infection in Chinese population. © 2005 Blackwell Publishing Asia Pty Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/78069
ISSN
2015 Impact Factor: 3.322
2015 SCImago Journal Rankings: 1.190
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, WMen_HK
dc.contributor.authorHuang, Jen_HK
dc.contributor.authorXia, HHXen_HK
dc.contributor.authorFung, FMYen_HK
dc.contributor.authorTong, TSMen_HK
dc.contributor.authorCheung, KLen_HK
dc.contributor.authorHo, VYKen_HK
dc.contributor.authorLai, KCen_HK
dc.contributor.authorChan, CKen_HK
dc.contributor.authorChan, AOOen_HK
dc.contributor.authorHui, CKen_HK
dc.contributor.authorLam, SKen_HK
dc.contributor.authorWong, BCYen_HK
dc.date.accessioned2010-09-06T07:38:49Z-
dc.date.available2010-09-06T07:38:49Z-
dc.date.issued2005en_HK
dc.identifier.citationJournal Of Gastroenterology And Hepatology, 2005, v. 20 n. 6, p. 935-940en_HK
dc.identifier.issn0815-9319en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78069-
dc.description.abstractBackground: Rabeprazole in combination with amoxicillin and metronidazole (RAM) has been shown to be an effective second-line treatment of Helicobacter pylori infection. The effects were compared of 7-day low-dose and high dose rabeprazole in RAM for the primary treatment of H. pylori infection in Chinese patients. Methods: Helicobacter pylori-positive dyspeptic patients were randomized to receive either (i) rabeprazole 10 mg, amoxicillin 1000 mg and metronidazole 400 mg (RAM-10) or (ii) high-dose rabeprazole 20 mg, amoxicillin 1000 mg and metronidazole 400 mg (RAM-20), each given twice daily for 7 days. Helicobacter pylori eradication was confirmed by 13C-urea breath test 5 weeks after stopping medications. Side-effects of treatments were documented. Results: A total of 120 patients were eligible for analysis. By intention-to-treat and per-protocol analysis, the eradication rates were 83% and 86% in the RAM-10 group and 75% and 76% in the RAM-20 group, respectively (P = 0.26 and P = 0.17). Both regimens were well-tolerated and compliance was >98% in both groups. Conclusions: Low-dose rabeprazole in combination with amoxicillin and metronidazole is an effective, economical and well-tolerated therapy for the treatment of H. pylori infection in Chinese population. © 2005 Blackwell Publishing Asia Pty Ltd.en_HK
dc.languageengen_HK
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGHen_HK
dc.relation.ispartofJournal of Gastroenterology and Hepatologyen_HK
dc.subject.mesh2-Pyridinylmethylsulfinylbenzimidazolesen_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAged, 80 and overen_HK
dc.subject.meshAmoxicillin - administration & dosage - therapeutic useen_HK
dc.subject.meshAnti-Bacterial Agents - administration & dosage - therapeutic useen_HK
dc.subject.meshBenzimidazoles - administration & dosage - therapeutic useen_HK
dc.subject.meshBiopsyen_HK
dc.subject.meshDose-Response Relationship, Drugen_HK
dc.subject.meshDrug Therapy, Combinationen_HK
dc.subject.meshDyspepsia - drug therapy - epidemiology - etiologyen_HK
dc.subject.meshEndoscopy, Gastrointestinalen_HK
dc.subject.meshEnzyme Inhibitors - administration & dosage - therapeutic useen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHelicobacter Infections - complications - drug therapy - epidemiologyen_HK
dc.subject.meshHelicobacter pylori - isolation & purificationen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMetronidazole - administration & dosage - therapeutic useen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshOmeprazole - administration & dosage - analogs & derivatives - therapeutic useen_HK
dc.subject.meshPrevalenceen_HK
dc.subject.meshProton-Translocating ATPases - antagonists & inhibitorsen_HK
dc.subject.meshPyloric Antrum - microbiology - pathologyen_HK
dc.subject.meshRetrospective Studiesen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleLow-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patientsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0815-9319&volume=20&issue=6&spage=935&epage=940&date=2005&atitle=Low-dose+rabeprazole,+amoxicillin+and+metronidazole+triple+therapy+for+the+treatment+of+Helicobacter+pylori+infection+in+Chinese+patientsen_HK
dc.identifier.emailWong, BCY:bcywong@hku.hken_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1400-1746.2005.03889.xen_HK
dc.identifier.pmid15946144-
dc.identifier.scopuseid_2-s2.0-21244433881en_HK
dc.identifier.hkuros99103en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-21244433881&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume20en_HK
dc.identifier.issue6en_HK
dc.identifier.spage935en_HK
dc.identifier.epage940en_HK
dc.identifier.isiWOS:000229282400020-
dc.publisher.placeAustraliaen_HK
dc.identifier.scopusauthoridWong, WM=7403972413en_HK
dc.identifier.scopusauthoridHuang, J=7403635051en_HK
dc.identifier.scopusauthoridXia, HHX=8757161400en_HK
dc.identifier.scopusauthoridFung, FMY=7003833944en_HK
dc.identifier.scopusauthoridTong, TSM=7102587364en_HK
dc.identifier.scopusauthoridCheung, KL=8612107300en_HK
dc.identifier.scopusauthoridHo, VYK=8612107400en_HK
dc.identifier.scopusauthoridLai, KC=7402135595en_HK
dc.identifier.scopusauthoridChan, CK=7404813960en_HK
dc.identifier.scopusauthoridChan, AOO=7403167965en_HK
dc.identifier.scopusauthoridHui, CK=7202876933en_HK
dc.identifier.scopusauthoridLam, SK=7402279473en_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats